A 14-year-old girl from Mumbai presents with a 6-week history of progressive pain and swelling over the proximal tibia. She has a history of bilateral retinoblastoma treated with chemotherapy 8 years ago. On examination, there is a warm, firm mass over the proximal tibia. X-ray reveals a mixed lytic and sclerotic lesion with cortical disruption. Alkaline phosphatase is elevated at 520 U/L. What is the most important next step in management after confirming the diagnosis with biopsy?

Explanation

## Osteosarcoma in the Context of Hereditary Retinoblastoma ### Clinical Context: RB1 Mutation & Secondary Malignancy **Key Point:** Patients with hereditary retinoblastoma (bilateral or familial) carry a germline mutation in the **RB1 gene** and have a significantly increased risk of developing secondary malignancies, including osteosarcoma, soft tissue sarcoma, and melanoma. This patient's history of bilateral retinoblastoma indicates hereditary disease and RB1 mutation carrier status. **High-Yield:** Osteosarcoma in RB1 mutation carriers: - Occurs at a younger age (often <15 years) - May be multifocal - Has a worse prognosis than sporadic osteosarcoma - Still requires aggressive multimodal therapy (chemotherapy + surgery) - Chemotherapy is NOT contraindicated despite prior chemotherapy exposure ### Why Neoadjuvant Chemotherapy Is the Standard of Care | Aspect | Rationale | |--------|----------| | **Tumor downsizing** | Reduces soft tissue extension and improves surgical margins | | **Micrometastatic disease** | ~20% have occult pulmonary metastases at diagnosis; chemotherapy addresses systemic disease | | **Histologic response** | Good chemotherapy response (>90% necrosis) is a strong prognostic factor | | **Limb salvage** | Neoadjuvant approach often allows wide resection with limb preservation rather than amputation | | **Survival benefit** | 5-year survival with multimodal therapy: ~70% (vs. ~20% with surgery alone) | ### Standard Neoadjuvant Chemotherapy Regimen **Mnemonic:** **MAP = Methotrexate, Adriamycin (doxorubicin), Cisplatin** — the classic osteosarcoma regimen. 1. **Methotrexate** — high-dose (8–12 g/m²) with leucovorin rescue 2. **Doxorubicin (Adriamycin)** — 75 mg/m² IV 3. **Cisplatin** — 100–120 mg/m² IV Typically given as 2–3 cycles preoperatively, then surgical resection, then 3–4 cycles postoperatively. ### Management Algorithm ```mermaid flowchart TD A[Osteosarcoma confirmed on biopsy]:::outcome --> B[Staging: CT chest, bone scan]:::action B --> C{Metastases present?}:::decision C -->|No| D[Neoadjuvant chemotherapy MAP]:::action C -->|Yes| E[Palliative/adjuvant chemotherapy]:::action D --> F[Reassess with imaging]:::action F --> G[Wide surgical resection]:::action G --> H[Assess histologic response]:::decision H -->|Good >90% necrosis| I[Adjuvant chemotherapy MAP]:::action H -->|Poor <90% necrosis| J[Intensified adjuvant therapy]:::action I --> K[Long-term surveillance]:::outcome J --> K ``` ### Why Other Options Are Incorrect **Clinical Pearl:** Even in patients with prior malignancy history, the proven survival benefit of multimodal therapy (chemotherapy + surgery) far outweighs the risk of secondary chemotherapy toxicity. Omitting chemotherapy significantly worsens prognosis. **Citation:** Pediatric Oncology Group (POG) and Children's Oncology Group (COG) protocols; Enneking surgical staging; Harrison 21e Ch 101.